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Abstract
Background: Several studies have established Glioblastoma Multiforme (GBM) prognostic and predictive models based on
age and Karnofsky Performance Status (KPS), while very few studies evaluated the prognostic and predictive significance of
preoperative MR-imaging. However, to date, there is no simple preoperative GBM classification that also correlates with a
highly prognostic genomic signature. Thus, we present for the first time a biologically relevant, and clinically applicable
tumor Volume, patient Age, and KPS (VAK) GBM classification that can easily and non-invasively be determined upon
patient admission.
Methods: We quantitatively analyzed the volumes of 78 GBM patient MRIs present in The Cancer Imaging Archive (TCIA)
corresponding to patients in The Cancer Genome Atlas (TCGA) with VAK annotation. The variables were then combined
using a simple 3-point scoring system to form the VAK classification. A validation set (N= 64) from both the TCGA and
Rembrandt databases was used to confirm the classification. Transcription factor and genomic correlations were performed
using the gene pattern suite and Ingenuity Pathway Analysis.
Results: VAK-A and VAK-B classes showed significant median survival differences in discovery (P = 0.007) and validation sets
(P = 0.008). VAK-A is significantly associated with P53 activation, while VAK-B shows significant P53 inhibition. Furthermore, a
molecular gene signature comprised of a total of 25 genes and microRNAs was significantly associated with the classes and
predicted survival in an independent validation set (P = 0.001). A favorable MGMT promoter methylation status resulted in a
10.5 months additional survival benefit for VAK-A compared to VAK-B patients.
Conclusions: The non-invasively determined VAK classification with its implication of VAK-specific molecular regulatory
networks, can serve as a very robust initial prognostic tool, clinical trial selection criteria, and important step toward the
refinement of genomics-based personalized therapy for GBM patients.
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Introduction
Glioblastoma Multiforme (GBM) is the most common primary
malignant brain tumor in adults. In the United States, more than
10,000 patients per year are newly diagnosed with GBM [1].
Despite existing multimodal treatment approaches, which nor-
mally include surgical resection followed by adjuvant radio-
chemotherapy, the median overall survival remains at
14.6 months [2].
Despite our increasing knowledge of GBM molecular biology
with the identification of GBM molecular subclasses and novel
possibly targetable pathways [3,4,5], presurgical survival predic-
tion is largely based on clinical factors such as age and KPS
[6,7,8,9,10,11,12]. However, after invasive procedures and geno-
mic data collection, extent of resection [7,13,14,15] and molecular
criteria, such as O6-methylguanine-DNA-methyltransferase (MGMT)
promoter methylation, isocitrate dehydrogenase 1 (IDH1), or glioma
CpG island methylator phenotype (G-CIMP) status are significant
prognostic and predictive criteria [7,16,17,18].
With the recent upsurge of genomic discoveries and enhanced
imaging technologies, in particular MRI, additional prognostic
and predictive determinants for GBM patients are available.
Previously, tumor volumes determined by MRI were shown to be
a prognostic biomarker associated with survival in recurrent GBM
[19]. Furthermore, MRI phenotypes of GBM tumors identified
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differential underlying molecular tumor compositions [20,21,22].
Patient stratification based on molecular characteristics has
become increasingly important. As such, Hegi et al [2,23]
demonstrated a survival benefit in patients with methylation of
the MGMT promoter treated with combined Temozolomide
(TMZ) and radiotherapy, with median overall survival of 23.4
months compared with 12.6 months in the non-methylated group
[2]. Etienne and colleagues demonstrated that older patients, who
often have the De Novo (primary) form of GBM, have EGFR
overexpression which is responsible for increased angiogenesis,
edema, and invasion and might account for the decrease in
survival in elderly patients [24]; younger patients more often
exhibit a secondary form of glioblastoma that is associated with
TP53 mutation [24]. A recent study demonstrated that GBM can
be divided into four molecular subgroups [25], although, no
significant survival differences among the groups were observed.
Imaging has been shown to be able to non-invasively reflect
underlying tumor biology and genomics [20,21,22,26], thus, a
simple classification which incorporates imaging could improve
existing prognostic criteria in a clinically relevant way.
Therefore, in this study, we propose and validate a simple and
highly prognostic GBM classification system which incorporates
preoperative tumor volumetry along with age and KPS (VAK)
that allows for non-invasive preoperative predictions at patient
admission. We also determine the VAK associated cognate
microRNA-gene regulatory networks inherent to each class which
might allow for a class-specific therapeutic approach.
Figure 1. Volume, Age, KPS GBM patient survival. (A) Kaplan Meier analysis based on high versus low volumes of MRI T1 post-contrast images
and (B) Kaplan Meier analysis based on high and low volumes of peritumoral MRI T2/FLAIR signal intensity. (C) Left panel: A segmented right
temporal lobe glioblastoma is shown with volumes of necrosis (red), contrast enhancement (yellow) and edema/FLAIR (blue). (C) Right panel: Same
patient as on left demonstrating how 2D measurements were performed. (D) Correlation of Total Tumor Volume and mean lesion diameter of the
two largest orthogonal measures. Kaplan Meier survival analyses for (E) Age, (F) KPS and (G) Proportional Hazards Model for: Total Tumor Volume,
Age, and KPS.
doi:10.1371/journal.pone.0041522.g001
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Methods
The collection of the original material and data of The Cancer
Genome Atlas (TCGA) and The Cancer Imaging Archive (TCIA)
study was conducted in compliance with all applicable laws,
regulations and policies for the protection of human subjects, and
necessary IRB approvals were obtained [27]. The TCGA is a NCI
sponsored publicly available resource which has produced a multi-
dimensional genomic and clinical data set in GBM and other
cancers [27]. Image data used in this research were obtained from
TCIA (http://cancerimagingarchive.net/) sponsored by the Can-
cer Imaging Program, DCTD/NCI/NIH. This repository con-
tains the imaging corresponding to the patients of the TCGA.
GBM patients for the validation set were also obtained from the
REpository for Molecular BRAin Neoplasia DaTa (RE-
MBRANDT) [28].
Patient population
We identified 78 GBM patients from TCGA for whom full
annotation of Age, KPS, and MGMT methylation status, and
corresponding pretreatment MR imaging was available in the
TCIA. An independent validation dataset (N=64) comparable to
the discovery set with regard to lesion volume, age, KPS, gender,
and survival distribution across VAK-A and VAK-B patients was
collated using both the Rembrandt and TCGA/TCIA databases.
The prognostic VAK derived cognate microRNA-gene signature
was validated using an independent larger TCGA dataset
(N= 255).
Image Acquisition and Analysis
All images were downloaded from the TCIA. Image analysis
was performed as previously described by our group [20]. In brief,
3D Slicer (www.slicer.org), an open-source software platform
developed at our institution (Brigham and Women’s Hospital,
Harvard Medical School) for medical image processing and 3D
visualization of image data, was used for tumor volumetry
[29,30,31]; AIM Clear Canvas (http://www.clearcanvas.ca) was
used to measure lesion diameters (mean of two largest orthogonal
diameters (D1 and D2, Figure 1).
Volume-Age-KPS (VAK) classification
The Volume, Age, and KPS (VAK) classification was created as
follows. The tumor volume score was calculated for each patient.
Patients were divided into groups based on the median lesion
volume or lesion diameter (30,000 mm3/40 mm); those above the
median cutoff were defined as high volume group and those below
as low volume group. Patients were also stratified into 2 groups
based on median age cutoff (those $60 years and ,60 years) and
KPS (those with KPS= 100 and KPS ,100). A 3-point scoring
system was used to dichotomize the patients into VAK-A and
VAK-B groups (Table 1): Volume $30,000 mm3 or a lesion
diameter $40 mm =1 point; Age $60 years = 1 point, KPS
,100=1 point. The sum of the latter three points defines the
VAK classification. Those patients with 0 and 1 points were
defined as VAK-A, while those with 2 and 3 points were defined as
VAK-B (Table 1).
Methylation status (M) of the MGMT promoter was subse-
quently included in the VAK score to obtain the VAKM scores.
VAKM patients were grouped into methylated (VAK + M) and
non-methylated (VAK-M) groups.
Genomic Analysis
Affymetrix level 1 mRNA, Agilent level 2 microRNA, and Level
3 Illumina and HumanMethylation27 methylation data were
downloaded from the public TCGA data portal (October 2011)
(http://cancergenome.nih.gov/). Affymetrix CEL file analysis was
performed in R project, a free statistical computing software
(http://www.r-project.org/) using the Bioconductor platform
(http://www.bioconductor.org/). The Robust Multi-Array
(RMA) algorithm was used for normalization [32]. To determine
the MGMT promoter methylation status a median cutoff using the
level 3 beta-value present in the TCGA was used (Illumina probes:
An average of the following probes was used: MGMT_P272_R
and MGMT_P281_F; Human Methylation probes (cg12434587
and cg12981137) were selected according to the recent publication
by Bady et al [33].
In each patient, a total of 13,628 genes (22,267 hybridization
probes) and 555 microRNAs (1,510 hybridization probes) were
analyzed for significance and differential fold regulation in VAK-A
and VAK-B classes by Comparative Marker Selection [34] (CMS)
(Broad Institute, MIT, Cambridge, MA). The significant and
inversely expressed genes and microRNAs in VAK-A and VAK-B
were analyzed using Ingenuity Pathway Analysis (IPA) (www.
ingenuity.com).
microRNA Target Prediction and Rank Score
Potentially binding microRNAs for the top 100 VAK-A and
VAK-B associated genes were determined using miRWalk [35], a
database which predicts microRNA targets. For each molecule, a
VAK gene- and microRNA rank score consisting of the product of
four variables (P value, fold regulation, binding strength, and
number of targeted molecules) was assigned (Table 2). This VAK
rank score measures the degree of correlation of a molecule with
either VAK class, how strong the microRNA potentially binds to
an inversely correlated mRNA, and how many inversely
correlated top ranking mRNAs or microRNAs are targeted by
other high ranking molecules. A high ranking molecule is a highly
targeted and targeting molecule that is VAK-A or VAK-B specific,
thus, likely a strong regulator of the VAK-A or VAK-B phenotype.
The rank score for microRNAs is negative and the rank score for
mRNAs is positive since they are inversely expressed. The top
genes and microRNAs for each class (total N= 37) were analyzed
by IPA to generate the cognate VAK-A and VAK-B microRNA-
gene regulatory networks.
VAK-25-gene- and microRNA signature
Ingenuity Pathway Analysis revealed a highly connected
network of a total of 25 molecules to form the cognate
microRNA-gene networks associated with VAK-A (12 molecules)
and VAK-B classes (13 molecules). To account for the inverse
expression pattern and prognostic aspect of the genes and
microRNAs, these 25 molecules were then combined into a single
signature by using the ratio of the mean (x) microRNA/gene
expression of VAK-A/VAK-B molecules.
Table 1. VAK classification system.
3-point VAK classification system
Volume $30,000mm3 or $40mm diameter = 1 point
Age $60 years = 1 point
KPS ,100 = 1 point
VAK-A (good prognosis) = 0 and 1 points
VAK-B (poor prognosis) = 2 and 3 points
doi:10.1371/journal.pone.0041522.t001
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VAK 25 gene and microRNA signature~
x (VAK miRs)=x (VAKAgenes)
x (VAKBmiRs)=x(VAKB) genes)
Median cutoff was used to separate the patients into significant
survival groups based on the above VAK-25-gene- and microRNA
signature in an independent TCGA validation set (N= 255).
Ingenuity Transcription Factor Analysis
Ingenuity Pathway Transcription Factor Analysis was used to
identify the transcription factors that may be responsible for gene
expression changes observed in the VAK-A and VAK-B patient
groups. IPA predicts which transcription factors are activated or
inhibited to explain the upregulated and downregulated genes
observed across the VAK groups. The transcriptional regulation is
measured by the z-score. The basis for z-score predictions are
relationships in the molecular pathways (networks). The relation-
ships represent experimentally observed gene expression or
transcription events and they must be associated with a direction
of change that is either activating or inhibiting (as derived from the
literature compiled in the IngenuityH Knowledge Base). A z-score
of below or above 2 is considered significant.
Statistical Analysis
Kaplan-Meier method and log-rank test were used to compute
overall median survival. Cox proportional hazards likelihood ratio
was used for direct comparison and relative survival effects of the
examined VAK variables. The statistical analyses were performed
using Microsoft Excel 2010 and JMP Pro 10.0 (SAS, Cary NC)
software packages.
Results
In order to create a non-invasive simple GBM classification that
can be determined upon patient admission in every clinical setting,
we compared the prognostic significance of the two most
frequently used MRI sequences, T1 post-contrast and T2/FLAIR.
Our data show that the total tumor volume corresponding to T1
post-contrast enhancing and necrotic tumor parts is a stronger
prognostic criterion than the volume of peritumoral T2/FLAIR
signal when using a median cutoff (Figures 1A and 1B, Table S1).
Stratification of GBM patients based on their total tumor volumes
(contrast enhancement + necrosis) or tumor diameter yielded a
trend toward longer survival with smaller lesions (P = 0.14,
Survival: 12 vs. 18.5 months) when considering median cutoff
(30,000 mm3) as previously described in the literature [36]. The
mean of the largest two orthogonal diameters of the lesion highly
correlated with the total tumor volume (R2= 0.82, Figures 1C and
1D, Table S1) and thus a standard 2D lesion diameter could be
used as a surrogate for tumor volume. We further hypothesized
that by utilizing additional known prognostic factors we could
augment the prognostic value of either variable by creating a
simple classification. Similar as for tumor volume, we analyzed two
additional variables: Age and Karnofsky Performance Status
(KPS). Both Age and KPS independently did not yield significance
(Age: P= 0.2, Survival: 13 vs. 18 months; KPS: P= 0.23, Survival:
13.5 vs. 20 months) (Figures 1E, 1F, and 1G, Table S1). However,
when we combined Volume, Age, and KPS to form the VAK
classification using an easy-to-use 3-point system, we achieved a
significant survival segregation of the patient population
(P= 0.007, Survival: 12 vs. 20 months) (Figure 2A, Table 1,
Table S2). We termed the two patient groups VAK-A and VAK-
B, whereas VAK-A demonstrated a favorable and VAK-B an
unfavorable prognostic significance (Figure 2, Table S2). As
expected, tumor volume, age, and KPS were significantly
associated with either VAK-A and VAK-B classes (Figures 2B
and 2C). For validation, we collated a VAK confirmation set
consisting of patients (N= 64) from both the Rembrandt and
TCGA databases that were not used in the discovery set
(P = 0.0087, Survival: 13 vs. 18 months) (Figure 2D, Table S2).
A merge of discovery and validation sets yielded a VAK-A survival
advantage of 20 versus 12.3 months in 142 patients (P,0.0001)
while the VAK classification clearly was superior when corrected
for Age and KPS (Figure 2E, Table S2).
We then sought to determine the VAK associated molecular
tumor configuration. To this end, the most significantly differen-
tially regulated genes across VAK-A and VAK-B were identified
and transcription factor analysis predicted the tumor suppressor
P53 to be the only transcriptional regulator significantly activated
in VAK-A, while inactivated in VAK-B (z-score = +/22.7
respectively) (Figure 3A, Table S3). For additional molecular
characterization of VAK, we identified the VAK-A and VAK-B
cognate gene and microRNA networks potentially contributing to
the observed survival difference. We assigned a combined rank
score to every molecule. The rank score consisted of the following
variables: Class-specific inverse microRNA-gene fold regulation, P
value, number of targeted and significant inversely expressed
molecules, and average binding predictions of the targeted or
targeting molecules (Figure 3B, Table 2). The high positive or high
negative rank scores thus reflect the positive or negative
correlation and the VAK class specific importance of a molecule
(Figure 3B and 3C). The top inversely correlated VAK-A and
VAK-B predicted genes and microRNAs (Figure 3B) analyzed by
IPA resulted in 25 molecules, while 12 molecules (3 microRNAs, 9
mRNAs) fell into VAK-A and 13 molecules (5 microRNAs, 8
mRNAs) fell into VAK-B (Figure 3C).
In order to validate the prognostic power of the 25 VAK-
derived molecules, we collated an independent larger TCGA
gene- and microRNA expression set (N= 255 patients) and applied
the VAK-derived 25 gene- and microRNA signature (Figure 3D,
Table S4) by means of the gene signature equation detailed in the
Table 2. Gene and microRNA Ranking.
Gene and microRNA rank score based on product of 4 variables
P-value Differential expression across VAK-A/VAK-B classes
Fold Regulation Differential fold regulation across VAK-A/VAK-B classes
Binding Strength Number of algorithms predicting microRNA-gene bindings
Targeted Molecules Number of inversely expressed molecules targeted within same class
doi:10.1371/journal.pone.0041522.t002
A Novel Volume-Age-KPS Glioblastoma Classification
PLoS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e41522
methods. When we considered a median cutoff using the 25-gene-
and microRNA signature, the 255 patients were segregated into
significantly different survival groups (P = 0.001, Survival: 13 vs.
18 months) (Figure 3D, Table S4). When considering MGMT
status with the VAK-A and VAK-B patient groups, our data show
that a favorable MGMT promoter methylation status (discovery
set, N= 78) resulted in a 10.5 months median survival advantage
for VAK-A compared to VAK-B patients (Figure 4). Interestingly,
VAK-B patients’ MGMT status yielded only a 1 month survival
difference both with and without TMZ treatment, while VAK-A
patients appear to benefit from a favorable MGMT status both
with (7.5 months) and without (3 months) Temozolomide therapy
(Figure S1).
The 25-gene- and microRNA signature together with available
annotation of Age and KPS in the 255 patient dataset also yielded
two very distinct survival groups (P,0.0001, Survival: 11.5 vs.
18.5 months) (Figure S2A, Table S5). Analysis of the gene
signature’s prognostic significance together with age, and KPS
with changing MGMT promoter methylation status yielded
similar results as for the volume, age, and KPS classification
(Figure S2B, Table S6). When analyzing survival differences of the
continuous VAK score, such as VAK 0, 1, 2, and 3 points, we
observe a point dependent decrease in median survival (24.9, 20,
13, and 10.5 months respectively), whereas 0 and 1 points, as well
as 2 and 3 points cluster into two distinct survival groups, thus,
supporting the dichotomized VAK-A (0 and 1 points) and VAK-B
(2 and 3 points) classification (Figure S3).
Thus, VAK establishes an initial non-invasive GBM patient
stratification with clinical and molecular significance.
Discussion
Survival in newly admitted presurgical patients has most often
been predicted by clinical factors, most commonly Age and KPS,
[6,7,9,10,12]. Nevertheless, here we show that preoperative MRI
based total tumor volume is of stronger prognostic significance as
shown by the proportional hazards test (Figure 1G) and, when
Figure 2. Volume, Age, KPS (VAK) classification and phenotype. Volume, Age, KPS (VAK)-A and B classes showing (A) Kaplan Meier survival
plot (B) representative MRI images for VAK-A and VAK-B patients and (C) Mean volume, Age, and KPS in VAK-A and VAK-B classes. (D) VAK-A and
VAK-B survival validation in an independent patient set (N= 64) and (E) combination of the discovery and validation set (N = 142) for patient with full
VAK annotaiton including the Proportional Hazards Model correcting for Age and KPS.
doi:10.1371/journal.pone.0041522.g002
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paired with age and KPS, creates a robust survival classification
for all preoperative GBM patients with availability of tumor
volume, age, and KPS annotation (Figures 1 and 2). A frequently
used prognostic GBM and Anaplastic Astrocytoma classification is
the Recursive Partitioning Analysis (RPA) [37]. A direct compar-
ison to VAK is limited as RPA requires additional variables such
as surgical resection, neurological and mental status to allow for
prognostic classification of all patients. These variables are not
present in the TCGA dataset. However, when we create a 3-tier
VAK classification to match the three RPA classes in the same
dataset where RPA annotation is available, we see a more
significant median survival difference between the extremes of
VAK groups relative to the RPA classification (Figure S4). This
underscores the fact that preoperative volume should be consid-
ered in initial prognostic predictions together with age and KPS in
GBM patients. When comparing MGMT promoter methylation
status across VAK-A and VAK-B; our data demonstrates that
VAK-A patients take more advantage of both a favorable MGMT
methylation status and Temozolomide therapy (Figure 4, Figur-
es S1 and S2). This significant survival difference observed in
VAK-A patients may occur due to the longer survival in general
and thus prolonged exposure to therapy, however, even in the
absence of TMZ, VAK-A patients with a favorable MGMT status
show a 3.5 fold increased median survival compared to VAK-B
patients, although 35% of the Temozolomide untreated group still
received radiotherapy, compared to 95% of the Temozolomide
treated group (Figure S1, left panel). This potentially demonstrates
a unique underlying molecular tumor composition in VAK-A and
VAK-B GBM patients which is further corroborated by the
distinct genomic signature of both gene- and microRNA cognate
networks inherent to VAK-A and VAK-B. More importantly, the
VAK-derived 25-gene- and microRNA signature is significantly
prognostic in an independent validation set and represents an
independently significant variable together with age and KPS in
the proportional hazards test. The fact that the latter three
variables are independent and significant prognostic criteria is an
additional rationale for the strength of a combined VAK-genomic
classification. Whole genome expression- and transcription factor
analysis predicts P53 to be significantly activated in VAK-A, while
inactivated in VAK-B patients (Figure 3A; Table S3). The ability
to preoperatively predict P53 activation status based on the
proposed non-invasive and simple classification supports the
association of VAK-A and VAK-B with distinct underlying
molecular signatures. Furthermore, VAK-A predominantly con-
tains down-regulated oncomirs [38,39,40] binding to up-regulated
tumor suppressor genes [41,42,43], while VAK-B predominantly
contains down-regulated tumor suppressor microRNAs [44,45,46]
binding to up-regulated oncogenes [46,47,48,49,50] (Figure 3C).
Taken together, this suggests that the VAK prognostic classifica-
tion carries a unique molecular configuration driving or inhibiting
oncogenesis in GBM.
This classification is important as it demonstrates that an initial
patient classification based on very robust survival variables such
as tumor volume, age, and KPS (VAK) can be determined upon
patient admission in any clinical setting capable of MRI and
should be considered a first step. Interestingly, we found that the
tumor volume was highly correlated (R2 = 0.82, Figure 1D) with
the tumor diameter and thus can be used as an accurate marker
for the tumor volume. This is important as volumetric measure-
ments require more time and manpower, while tumor diameter is
Figure 3. VAK molecular characterization. (A) TP53 activation and inhibition across VAK-A and VAK-B patient classes together with molecular
regulatory networks of differentially regulated genes. (B) VAK-A and VAK-B classes with corresponding top differentially expressed genes- and
microRNAs and (C) graphical representation of the prognostic cognate gene- and microRNA VAK-A and VAK-B networks consisting of a total of 25
molecules. (D) Kaplan Meier survival plot using the VAK-derived 25 gene- and microRNA signature in an independent TCGA validation set of 255
patients.
doi:10.1371/journal.pone.0041522.g003
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easy to obtain and can be done by the radiologist or treating
clinician at the imaging workstation. As more refined clinical and
molecular variables become available during the treatment course,
class refinement in addition to the VAK classification can yield
more accurate insights into the role of potential targetable and
survival/therapy predictive molecular factors. In particular, based
on our data one can hypothesize that a combined classification
using VAK together with the VAK-derived 25-gene- and
microRNA signature and MGMT status can have a very robust
prognostic and predictive significance for GBM patients. Further-
more, the VAK classification has the potential to facilitate patient
selection for clinical trials. As an example patients with VAK score
2 and 3 (VAK-B class) having a poor survival and small benefit
from multimodal therapy and favorable MGMT status (Figure 4,
Figures S1 and S2), can be selected as candidates for new clinical
trials rather than selecting the standard recurrent tumor patient
group. The gene- and microRNA class stratification offered by the
VAK classification can allow for novel Temozolomide and
radiotherapy regimens based on the relative survival gain across
VAK-A and VAK-B patient groups, or shed insight to possibly
future agents which can be specifically developed to target the
molecular signature of either VAK-A or VAK-B patients. Taken
together, this suggests that the VAK classification is prognostic and
predictive in nature.
Despite the strong evidence across discovery and validation sets,
prospective validation of the joint VAK clinical/molecular
classification is needed to confirm the potential therapeutic
significance. However, the VAK classification with its implication
of VAK-specific molecular regulatory networks, can serve as a
very robust prognostic tool, clinical trial selection criteria, and
important step toward the refinement of personalized therapy for
GBM patients.
Supporting Information
Figure S1 VAK classification with and without MGMT
methylation (VAKM) in the presence and absence of
Temozolomide therapy.
(TIF)
Figure S2 VAK-derived 25 gene- and microRNA signa-
ture clinical significance (A) Kaplan Meier survival plot
using the VAK-derived 25 gene- and microRNA signature
together with Age and KPS in an independent TCGA set
of 255 patients. (B) Refined VAK classification by introducing
MGMT promoter methylation by using the VAK-derived gene-
and microRNA signature together with Age and KPS in a larger
independent dataset (N= 255).
(TIF)
Figure S3 Kaplan Meier survival based on the contin-
uous VAK score, demonstrating the median survival
decrease with a higher VAK score.
(TIF)
Figure S4 Comparison of the 3-tier-VAK and RPA
survival classification.
(TIF)
Table S1 Calculations for Kaplan Meier plots for Total
Tumor Volume, FLAIR signal, KPS, and age.
(TIF)
Table S2 Calculations for VAK-A and VAK-B Kaplan Meier
survival for the discovery, validation, and combined discovery and
validation sets.
(TIF)
Figure 4. VAK MGMT model. Refined VAK classification with MGMT promoter methylation stratification, demonstrating the increased survival
benefit for VAK-A with favorable MGMT status.
doi:10.1371/journal.pone.0041522.g004
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Table S3 Ingenuity Pathway Analysis z-scores for TP53
and other transcriptional regulators in VAK-A and VAK-
B classes.
(TIF)
Table S4 Calculations for Kaplan Meier survival corre-
sponding to the VAK-25-gene- and microRNA signature
in an independent TCGA data set (N=255).
(TIF)
Table S5 Calculations for Kaplan Meier survival with
age, KPS, and VAK-25-gene- and microRNA signature in
the independent TCGA data set (N=255) and propor-
tional hazards ratio showing independent prognostic
significance for the latter three variables.
(TIF)
Table S6 Calculations for VAKM Kaplan Meier survival
for the discovery and the independent larger TCGA data
set.
(TIF)
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